Abstract

Variable agreement exists between different lipoprotein (a) [Lp(a)] measurement methods, but their clinical relevance remains unclear. The predictive value of Lp(a) measured by two different assays [Randox and University of California, San Diego (UCSD)] was determined in 623 coronary artery disease (CAD) cases and 948 controls in a case-control study within the EPIC-Norfolk Prospective Population Study. Participants were divided into sex-specific quintiles, and by Lp(a) <50 versus ∼50 mg/dl, which represents the 80th percentile in northern European subjects. Randox and UCSD Lp(a) levels were strongly correlated; Spearman's correlation coefficients for men, women, and sexes combined were 0.905, 0.915, and 0.909, respectively (P< 0.001 for each). The >80th percentile cutoff values, however, were 36 mg/dl and 24 mg/dl for the Randox and UCSD assays, respectively. Despite this, Lp(a) levels were significantly associated with CAD risk, with odds ratios of 2.18 (1.58-3.01) and 2.35 (1.70-3.26) for people in the top versus bottom Lp(a) quintile for the Randox and UCSD assays, respectively. This study demonstrates that CAD risk is present at lower Lp(a) levels than the currently suggested optimal Lp(a) level of <50 mg/dl. Appropriate thresholds may need to be population and assay specific until Lp(a) assays are standardized and Lp(a) thresholds are evaluated broadly across all populations at risk for CVD and aortic stenosis.

Highlights

  • Variable agreement exists between different lipoprotein (a) [Lp(a)] measurement methods, but their clinical relevance remains unclear

  • The European Atherosclerosis Society (EAS) Consensus Panel has recommended that Lp(a) levels should be measured in patients with an intermediate or high CVD risk and that desirable Lp(a) levels are below the 80th percentile of the population distribution, which roughly corresponded to 50 mg/dl in a Copenhagen population of 6,000 subjects [2]

  • This study evaluated population and assay thresholds for the predictive value of Lp(a) for the risk of coronary artery disease (CAD) with two different assays measured in the same subjects

Read more

Summary

Introduction

Variable agreement exists between different lipoprotein (a) [Lp(a)] measurement methods, but their clinical relevance remains unclear. The predictive value of Lp(a) measured by two different assays [Randox and University of California, San Diego (UCSD)] was determined in 623 coronary artery disease (CAD) cases and 948 controls in a case-control study within the EPIC-Norfolk Prospective Population Study. The >80th percentile cutoff values, were 36 mg/dl and 24 mg/dl for the Randox and UCSD assays, respectively. Lp(a) levels were significantly associated with CAD risk, with odds ratios of 2.18 (1.58–3.01) and 2.35 (1.70–3.26) for people in the top versus bottom Lp(a) quintile for the Randox and UCSD assays, respectively. L. Witztum are coinventors and receive royalties from patents owned by the University of California, San Diego (UCSD) on oxidation-specific antibodies and of biomarkers related to oxidized lipoproteins. Based on genetic variants of this protein, large interindividual differences in apo(a) isoform size exist

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.